Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 81 ~ 100 of 25816, Page 5 of 1292
81. U.S. FDA Accepts sNDAs for PIFELTRO (doravirine) and DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) - 01/22/2019
 MERCK
  Potential New Indication Would Expand Use to Allow Treatment-Experienced Adults Living with HIV-1 Whose Virus is Suppressed to Switch to PIFELTRO (in Combination with Other Antiretrovirals) or DELSTRIGO
82. Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB - 01/22/2019
 Medtronic
  Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency
83. Study: Oncologists Want More Education About LGBTQ Issues - 01/22/2019
 American Cancer Society
  A survey of oncologists finds that most say they dont know enough about how to treat people in the lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) community, but want to learn more.
84. Trampoline parks may cause more severe trauma than at home trampoline use - 01/22/2019
 American Academy of Orthopaedic Surgeons
  New research compares injuries sustained at commercial jump parks versus home trampolines
85. Lifestyle Choices May Help Glaucoma Patients Preserve Eyesight - 01/22/2019
 American Academy of Ophthalmology
  American Academy of Ophthalmology offers advice on how people can take control of their health beyond medications and surgery
86. Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation - 01/21/2019
 Abbott
  With approval of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
87. New Data Reinforce Benefits of Abbotts BurstDR Spinal Cord Stimulation for People Living with Chronic Pain - 01/19/2019
 Abbott
  Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR stimulation / Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices / Additional data further showed switching from other types of SCS therapies to Abbotts BurstDR stimulation significantly reduced pain and the need for opioid medication
88. ACS Cancer Prevention Blueprint Targets Controllable Risk Factors - 01/18/2019
 American Cancer Society
  This second chapter in the American Cancer Society Cancer Control Blueprint describes what we know about risk factors for cancer. It provides strategies people can use to help avoid those risk factors. It also offers strategies that cities, states, and communities can use to help people avoid them. It''s co-authored by staff researcher Susan Gapstur, PhD, MPH, senior vice president of Behavioral and Epidemiology Research.
89. American Academy of Orthopaedic Surgeons approves clinical practice guideline for management of acute compartment syndrome - 01/17/2019
 American Academy of Orthopaedic Surgeons
  Evidence-based diagnosis and treatment recommendations for traumatic, severe limb injuries
90. Statement from FDA Commissioner, on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths - 01/17/2019
 U.S. FOOD & DRUG ADMINISTRATION
91. World Cancer Day 2019: I Am and I Will. - 01/17/2019
 American Cancer Society
  Monday, February 4th is World Cancer Day, when organizations and people around the world unite to raise awareness about cancer and work to make it a global health priority.
92. Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery - 01/17/2019
 Medtronic
  Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids
93. Japanese Red Cross Society Selects Abbott Technology to Screen Country''s Blood and Plasma Supply - 01/17/2019
 Abbott
  LONG-TERM AGREEMENT BETWEEN JAPANESE RED CROSS SOCIETY AND ABBOTT BRINGS TOGETHER TWO GLOBAL LEADERS IN BLOOD AND PLASMA SCREENING, HELPING ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY ACROSS JAPAN
94. FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy - 01/16/2019
 U.S. FOOD & DRUG ADMINISTRATION
95. Abbott To Acquire Cephea Valve Technologies, Inc. - 01/16/2019
 Abbott
  Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
96. Statement from FDA Commissioner, Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies - 01/15/2019
 U.S. FOOD & DRUG ADMINISTRATION
97. Medtronic Launches Mobile App That Communicates Directly with World''s First Smartphone-Connected Pacemakers - 01/15/2019
 Medtronic
  MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their Clinics
98. Personalized Treatment Benefits Kidney Cancer Patients - 01/15/2019
 Radiological Society of North America
  Patients who have risk factors for worsening kidney disease may benefit from personalized treatment plans / Researchers constructed a simulation model to assess the impact of different treatment approaches in patients with small renal tumors. /
99. AAOS Praises Introduction of Hospital Competition Act - 01/15/2019
 American Academy of Orthopaedic Surgeons
100. Mercks KEYTRUDA (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS 10) - 01/14/2019
 MERCK
  Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI)
<<  <  [1]  [2]  [3]  [4]  [5[6]  [7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com